

**Table S1.** Number of selected immune genes in each sub-pathway

<b>Sub-pathway annotation</b>	<b>No. of genes</b>
Release of cancer cell antigens	74
Cancer antigen presentation	101
T-cell priming and activation	150
Immune cell localization to tumors	292
Stromal Factors	102
Recognition of cancer cells by T-cells	111
Killing of cancer cells	179
Myeloid cell activity	260
NK cell activity	28
Cell cycle and proliferation	54
Tumor-intrinsic factors	155
Immunometabolism	101
Common signaling pathways: Wnt, TGF- $\beta$ , NF- $\kappa$ B, TLR, and Jak/STAT	162
<b>Total Immune Genes</b>	<b>757</b>
Known GWAS genes from prior HNSCC	115
Human leukocyte antigen region (6p21.2)	44
Killer cell immunoglobulin-like receptors cluster	17
Innate Database	950
<b>Total combining genes</b>	<b>1576</b>

**Abbreviation:** GWAS, genome-wide association studies; HNSCC, head and neck squamous cell carcinoma; OPC, oropharyngeal cancers.

**Table S2.** Functional enrichment analyses of the top-ranked susceptibility genes using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO)

Pathway	Candidate genes presented	Background gene count	P-value
<b>Overall HNSCC susceptibility genes</b>			
Immunoglobulin complex	<i>ICAM5, HLA-DRB1, HLA-DQA1</i>	3 of 43	0.002
Regulation of leukocyte differentiation	<i>FANCA, HLA-DRB1</i>	2 of 261	0.047
<b>Non-OPC susceptibility genes</b>			
Cellular response to stress	<i>TP73, FANCA, IRAK2, TPM1, MGMT</i>	5 of 139	0.014
Neurotrophin signaling pathway	<i>TP73, IRAK2</i>	2 of 116	0.016
<b>OPC/HPV-positive OPC susceptibility genes</b>			
MHC class II protein complex	<i>HLA-DRB1, HLA-DRB5, HLA-DQA1, HLA-DRA, HLA-DMB, HLA-DQB2</i>	6 of 14	2.9x10 <sup>-15</sup>
Common signaling	<i>CDH2, CDH5, NTN1, LOXL2, HLA-DRB1, HLA-DRB5, HLA-DQA1, HLA-DRA, HLA-DMB, HLA-DQB2</i>	10 of 162	1.3x10 <sup>-12</sup>
Autoimmune thyroid disease	<i>HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-DQA1, HLA-DMB</i>	5 of 49	4.4x10 <sup>-8</sup>
<b>Risk factor sub-group susceptibility genes for Overall HNSCC (smoking, alcohol, overweight/obese)</b>			
Viral myocarditis	<i>CAPS8, HLA-DPB2, HLA-G, HLA-DOA</i>	4 of 56	3.4x10 <sup>-7</sup>
Regulation of T cell activation	<i>NFkB-p65, FANCA, CD6, CD68, CD74/HLA-DG, SOCS6, HLA-G, HLA-DOA, HLA-DPB2</i>	9 of 302	2.8x10 <sup>-6</sup>
Cell adhesion molecules	<i>CD6, CDH2, CDH5, HLA-G, HLA-DOA, HLA-DPB2</i>	6 of 139	7.8x10 <sup>-4</sup>

**Abbreviation:** HNSCC, head and neck squamous cell carcinoma; OPC, oropharyngeal cancers; HPV, human papillomavirus.

**Table S3.** The high-confident pair-wise protein-protein interaction (PPI) score, predicted by STRING (Search Tool for the Retrieval of Interacting Genes)

Interaction pairs		Evidence		Combined PPI score
Protein (node 1)	Protein (node 2)	Experimentally	Database	
CDH2	CDH5	0	0.9	0.92
IRAK2	NFkB-p65	0	0.9	0.93
CASP8	NFkB-p65	0	0.9	0.95
cKIT	SOCS6	0.47	0.9	0.97
<i>CD74/HLA-DG</i>	HLA-DOA	0.19	0.9	0.95
<i>CD74/HLA-DG</i>	HLA-DMB	0.38	0.9	0.99
<i>CD74/HLA-DG</i>	HLA-DRB5	0.35	0.9	0.99
<i>CD74/HLA-DG</i>	HLA-DQA1	0.70	0.9	0.99
<i>CD74/HLA-DG</i>	HLA-DQB2	0.41	0.9	0.99
<i>CD74/HLA-DG</i>	HLA-DRB1	0.86	0.9	0.99
<i>CD74/HLA-DG</i>	HLA-DRA	0.89	0.9	0.99
HLA-DMB	HLA-DOA	0.48	0.9	0.97
HLA-DMB	HLA-DQA1	0.27	0.9	0.96
HLA-DMB	HLA-DRB1	0.39	0.9	0.98
HLA-DMB	HLA-DRA	0.76	0.9	0.99
HLA-DOA	HLA-DRB5	0.20	0.9	0.93
HLA-DOA	HLA-DQB2	0.20	0.9	0.94
HLA-DOA	HLA-DRB1	0.20	0.9	0.94
HLA-DQA1	NCAM1/CD56	0	0.9	0.91
HLA-DQA1	HLA-DRB5	0.35	0.9	0.96
HLA-DQA1	HLA-DRB1	0.35	0.9	0.96
HLA-DQA1	HLA-DQB2	0.74	0.9	0.99
HLA-DQB2	HLA-DRA	0.30	0.9	0.95
HLA-DRA	HLA-DRB1	0.93	0.9	0.99
HLA-DRA	HLA-DRB5	0.93	0.9	0.99
HLA-DRB1	NCAM1/CD56	0	0.9	0.92
HLA-DRB1	HLA-DRB5	0.75	0.9	0.98
HLA-G	NCAM1/CD56	0	0.9	0.95